Stifel notes Precigen (PGEN) has completed the BLA submission of PRGN-2012, which comes on the heels of 2 financial announcements that together provide the company with significant runway to navigate the regulatory review and execute a commercial launch. The firm continues to see PRGN-2012 as clinically de-risked following Phase 2 data at ASCO24 and sees the likelihood-of-approval as high. Stifel doesn’t think the data is controversial, but believes the stock is trading at depressed levels on both balance sheet worries and a hesitation to underwrite commercial efforts for a new, yet-to-be validated market. The firm believes the Innovator 21 deal netting $8.5M in non-dilutive capital, along with the $79M PIPE sufficiently addresses the balance sheet overhang. Stifel has a Buy rating on the shares with a price target of $7.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGEN: